本帖最后由 老马 于 2013-3-13 13:43 编辑 1 O1 U8 Y4 w' E2 z
$ u' l! S- d) Y: b) x- q
健择（吉西他滨）+顺铂+阿瓦斯汀/ j) _, V5 ^& D* N
Gemzar +Cisplatin + Avastin
' U" Q. _; C2 A! t; H, i+ Zhttp://annonc.oxfordjournals.org/content/21/9/1804.full
& A, f. P P4 M9 W8 VOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 D3 j* ~- r' |8 V6 A
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( o. q. F# E& r. ^2 a+ A! KResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. $ b7 H; ~3 A% c! a5 v
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 818)
9 K; e2 P. R- H+ l* ?; ^% ]5 y华为网盘附件：% I; y0 b1 N+ p
【华为网盘】ava.JPG4 c# R U" U3 D9 R
|
显身卡
